# SPOT BIOSYSTEMS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spot-biosystems

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.spotbiosystems.com
- Total disclosed funding: $40M
- Latest round: Series A (Jun 17, 2026)
- Investors on record: 7

## About

Based in the US, Spot Biosystems is a biotechnology company focused on developing innovative gene delivery solutions using extracellular vesicles to enhance the safety and efficacy of gene therapies for genetic disorders.Spot Biosystems specializes in advancing gene delivery technologies, particularly targeting Duchenne muscular dystrophy. Founded in San Francisco, US, the company has strategically pivoted towards utilizing extracellular vesicles in its operations. They recently raised USD 40 million in series A funding from investors such as Advantech Capital and Tiger Jade Capital, which will support their gene delivery platform development. The company currently does not have any known subsidiaries or parent companies.Spot Biosystems specializes in a pioneering gene delivery platform utilizing extracellular vesicles (EVs) to enhance the safety and efficacy of gene therapies. This innovative technology targets various diseases with a primary focus on Duchenne muscular dystrophy, a severe genetic disorder. By enabling targeted and efficient delivery, Spot Biosystems aims to improve treatment outcomes for patients affected by genetic disorders. The company's products are primarily marketed in North America and Europe, engaging with biotech firms, research institutions, and healthcare providers focused on advanced therapies in the genetic space.Spot Biosystems generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions interested in gene therapy applications. The company’s business model includes project-based agreements and licensing fees for its EV-mediated delivery technology, with transactions typically involving upfront payments and milestone payments as development stages are achieved. Revenue is supported by the demand for innovative gene therapies and long-term partnerships in specialized therapeutic markets.In June 2026, Spot Biosystems raised USD 40 mn in series A funding, which will be utilized to advance their gene delivery platform and further develop their treatment for Duchenne muscular dystrophy. The company plans to expand its market presence into new geographic regions, including additional areas in Europe and Asia, by late 2026. This strategic growth will involve launching new products and enhancing collaborations within the biotechnology sector.

## Funding rounds

- Series A, Jun 17, 2026, $40M — IDG Capital, Shanda Capital, Stanford-StartX Fund, Advantech Capital, LDV Management, Saltagen Ventures, Tiger Jade Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Shanda Capital — Series A
- Stanford-StartX Fund — Series A
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series A
- LDV Management (https://capitalatlas.ai/funds/ldv-management) — Series A
- Saltagen Ventures (https://capitalatlas.ai/funds/saltagen-ventures) — Series A
- Tiger Jade Capital (https://capitalatlas.ai/funds/tiger-jade-capital) — Series A